Susanne Johansson

All other publications

Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:647-648
Real world experience of fingolimod after switching multiple sclerosis (MS) therapy; focus on natalizumab naive and experienced persons with MS, respectively
Forsberg L; Johansson S; Frisell T; Hillert J; Nilsson P; Dahle C; Sveningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:336-337
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1)
Johansson S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:285-286
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and efficacy of natalizumab
Johansson S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:284-285
The IMSE 2 study: a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod
Johansson S; Forsberg L; Nordin N; Hillert J; Svenningsson A; Lycke J; Burman J; Landtblom A-M; Walentin F; Martin C; Nilsson P; Dahle C; Piehl F; Olsson T